About Doctor Lindsay Rosenwald
As is one of the most prolific entrepreneurs in the field of biotechnology, Dr. Lindsay Rosenwald’s myriad contributions to that industry is as the Founder and Chairman of a Group of Companies. These ventures range from a firm that helps to facilitate and coordinate drug development and corporate development activities, to a global pharmaceutical development and health care investment firm specializing in the conception, nurturing, and support of new biotechnology companies.
After graduating from Abington High School in southeastern Pennsylvania in 1973, Dr. Rosenwald attended Pennsylvania State University as a Finance major. He graduated in 1977 as a member of Beta Gamma Sigma, a business school honor society, and moved on to Temple University’s School of Medicine. After graduating from Temple in 1983, Dr. Rosenwald took an internship at Abington Medical Hospital and remained in private medical practice until 1986. At that time, he moved to Wall Street to serve as a physician/financial analyst, a specialized combination of fields which very few boasted at that time.
In 1991, Dr. Rosenwald, in the 19 years since then has revolutionized the field of bioresearch and biotechnology. One of his portfolio companies hold the record for a drug, Arsenic Trioxide, moving most quickly from development to Food & Drug Administration approval. Cougar Biotechnology, another company founded by Dr. Rosenwald, was purchased by Johnson & Johnson in 2009 based solely on abiraterone acetate. This drug was not yet in phase III clinical trials for its application in the treatment of prostate cancer but was so promising that Johnson & Johnson purchased the company in a “short-term merger” for approximately $1 billion. Abiraterone acetate is also notable as having been based on a Traditional Chinese Medicine (TCM) practice. In addition to his activities which have provided capital and funding to many portfolio companies, Dr. Rosenwald also founded the Rosenwald Foundation, a nonprofit organization which has donated millions of dollars to support various scientific and medical education institutions. These funds and grants assist the groundbreaking scientists of today in research and development, forging the advancement of biotechnology into tomorrow.
Dr. Lindsay Rosenwald’s nearly 20-year track record in the fields of biotechnology, pharmaceutics, biomedicine, and finance have placed him at the forefront of cutting-edge research and development. The unique combination of disciplines he studied – medicine and finance – places him in a rare and unique position to identify opportunities to broaden the frontiers of high-tech medicine and finance those pioneers that work on those frontiers. With his rich and diverse background in a remarkably specialized industry, Dr. Rosenwald’s prolific achievements are matched by few in the industry.